Antileukotriene Agents Versus Long‐Acting Beta‐Agonists in Older Adults with Persistent Asthma: A Comparison of Add‐On Therapies

Altawalbeh, Shoroq M.; Thorpe, Carolyn T.; Zgibor, Janice C.; Kane‐Gill, Sandra L.; Kang, Yihuang; Thorpe, Joshua M.

doi:10.1111/jgs.14235

Cited by 5 publications

References 40 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences

Cazzola,

Page,

Hanania

et al. 2024

Drugs

View full text Add to dashboard Cite

Asthma and cardiovascular disease (CVD) often co-exist. When a patient has both conditions, management requires an approach that addresses the unique challenges of each condition separately, while also considering their potential interactions. However, specific guidance on the management of asthma in patients with CVD and on the management of CVD in patients with asthma is still lacking. Nevertheless, health care providers need to adopt a comprehensive approach that includes both respiratory and CVD health. The management of CVD in patients with asthma requires a delicate balance between controlling respiratory symptoms and minimising potential cardiovascular (CV) risks. In the absence of specific guidelines for the management of patients with both conditions, the most prudent approach would be to follow established guidelines for each condition independently. Careful selection of asthma medications is essential to avoid exacerbation of CV symptoms. In addition, optimal management of CV risk factors is essential. However, close monitoring of these patients is important as there is evidence that some asthma medications may have adverse effects on CVD and, conversely, that some CVD medications may worsen asthma symptoms. On the other hand, there is also increasing evidence of the potential beneficial effects of asthma medications on CVD and, conversely, that some CVD medications may reduce the severity of asthma symptoms. We aim to elucidate the potential risks and benefits associated with the use of asthma medications in patients with CVD, and the potential pulmonary risks and benefits for patients with asthma who are prescribed CVD medications.

show abstract

Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences

Cazzola,

Page,

Hanania

et al. 2024

Drugs

View full text Add to dashboard Cite

show abstract

A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma

Czira¹,

Turner²,

Martin³

et al. 2022

Respiratory Medicine

View full text Add to dashboard Cite

Management of patients with asthma or COPD and cardiovascular disease: risksversusbenefits

Ora¹,

Cavalli²,

Cazzola³

2020

Cardiovascular Complications of Respiratory Disorders

View full text Add to dashboard Cite

Antileukotriene Agents Versus Long‐Acting Beta‐Agonists in Older Adults with Persistent Asthma: A Comparison of Add‐On Therapies

Abstract: This study provides new evidence specific to older adults to help healthcare providers weigh the risks and benefits of these add-on treatments. Further subgroup analysis is needed to personalize asthma treatments in this high-risk population.

Cited by 5 publications

References 40 publications

Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences

Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences

A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma

Management of patients with asthma or COPD and cardiovascular disease: risksversusbenefits

Contact Info

Product

Resources

About